Apnimed banks $351.8m as FDA clock runs down on first-in-class sleep apnoea pill
The US drugmaker says its cash should last into the second quarter of 2028, well past an agency decision on its once-nightly combination therapy due by 28 February 2027.
Apnimed has told investors it has enough money to operate beyond the point at which the US Food and Drug Administration is due to rule on its obstructive sleep apnoea candidate. The company reported cash of $351.8m in its third-quarter update on 16 November 2026 and said that sum should fund operations into the second quarter of 2028.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Apnimed, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.